Jonathan E Lim
CIK 1283290 · Chairman & CEO · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$366.76M
Companies
5
Total Filings
53
Lifetime Open-Market Net
$2.17M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BOLD | Director | 653,479 | $2.48 | $1.62M | $0 | 5 | 2026-06-15 |
| MAZE | Director | 328,700 | $27.80 | $9.14M | $0 | 3 | 2026-06-10 |
| ERAS | Chairman & CEO | 19,456,216 | $18.30 | $356.00M | $4.71M | 13 | 2026-01-30 |
| Ignyta, Inc. (RXDX) Delisted | President, CEO and Director | 3,529,661 | $199.92 | $705.65M | $464.5K | 12 | 2017-12-28 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Chief Executive Officer | 710,000 | — | — | -$3.00M | 19 | 2010-02-08 |
Recent Filings · Page 5 of 6
53 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-12-04 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | — | -$157.0K | EDGAR |
| 2007-11-02 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | — | -$216.1K | EDGAR |
| 2007-10-16 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Exer (M) | +26,690 | $12.0K | EDGAR |
| 2007-10-02 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | — | -$209.8K | EDGAR |
| 2007-08-31 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +12,800 | -$94.8K | EDGAR |
| 2007-08-31 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −12,800 | -$112.8K | EDGAR |
| 2007-08-02 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | — | -$156.1K | EDGAR |
| 2007-07-02 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Mixed | +8,199 | -$148.6K | EDGAR |
| 2007-07-02 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −8,199 | -$78.6K | EDGAR |
| 2007-06-26 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Exer (M) | +96,313 | $37.6K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.